RESEARCH
KRAS mutations occur in 40% of colorectal cancers and predict resistance to anti-EGFR therapyA comprehensive review finds KRAS-mutant tumors are associated with increased recurrence risk and reduced survival, including in patients undergoing liver metastasis surgery. (Current Oncology)